Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

2023/08/16 by Peter C. Black, Catherine M. Tangen, Parminder Singh +13 · 2 citations
Immunology and Microbiology · Medicine · #Bladder and Urothelial Cancer Treatments #Immune responses and vaccinations #Urinary and Genital Oncology Studies

paper · doi:10.1016/j.eururo.2023.08.004

openalex publication_date 2023/08/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Cited by

• A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non–muscle-invasive Bladder Cancer
• Intravesical Administration of Durvalumab for High-risk Non–muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group